SARS-CoV-2

Complete solutions for your research and industry requirements

 

Biolegio has rapidly scaled up production capabilities to deliver primers and probes for RT-qPCR  SARS-CoV-2 testing and have been supplying laboratories and customers sufficient primer and probe sets to perform 10s of millions of tests throughout 2020 and 2021.

 

Following the demand from customers we have specifically focused on the production of the primer and probe sets described

in the assay protocols developed by Charité, Berlin/Erasmus MC/Public Health England and the US CDC. Available as Research Use Only Premixed Assay Kits, Individual primers and 5’ FAM probes at stock yields (25, 50 & 100nmol) or custom yields/bulk OEM volumes or with other 5’ fluorophore labels.

 

About Biolegio

Company DNA

Biolegio was founded in 1996 in Nijmegen, the Netherlands. The company's first production facility was located on the campus of the Radboud University Medical Centre in Nijmegen. Following several years of rapid growth we required more space to keep up with demand and relocated to new facilities.

 

 

 

This site, still located in Nijmegen, remains our headquarters today and offered the space we needed for expanding our endeavors. Over the years our product range has expanded from simple custom made DNA oligos to highly modified and specialised oligos, for countless different life science applications.

Biolegio now has over 20 years of experience with the synthesis of oligos with satisfied customers located all over the world. They use our products on a daily basis and benefit from our specialist knowledge within the field.

References

 

Dr. Ing. R.P.L. Rogier Louwen
Erasmus MC

By making use of the synthetic guide RNA’s provided by Biolegio, we now easily make a Cas9/gRNA (RNP) complex that together with or without a template (PCR product) can be transferred at high efficiencies into the eukaryotic cells by using lipofection methods.

Compared to the plasmid based genome editing procedures we observed less toxicity, increased specificity and remove the introduction of foreign DNA (plasmid backbone) into the eukaryotic cells. This makes the genome editing procedure much cleaner and therefore our group encourage colleagues in the field to start using synthetic guide RNAs.

Dr. Ing. R.P.L. Rogier Louwen (Erasmus MC)

By making use of the synthetic guide RNA’s provided by Biolegio, we now easily make a Cas9/gRNA (RNP) complex that together with or without a template (PCR product) can be transferred at high efficiencies into the eukaryotic cells by using lipofection methods.

Compared to the plasmid based genome editing procedures we observed less toxicity, increased specificity and remove the introduction of foreign DNA (plasmid backbone) into the eukaryotic cells. This makes the genome editing procedure much cleaner and therefore our group encourage colleagues in the field to start using synthetic guide RNAs.

Dr. Ing. R.P.L. Rogier Louwen (Erasmus MC)

By making use of the synthetic guide RNA’s provided by Biolegio, we now easily make a Cas9/gRNA (RNP) complex that together with or without a template (PCR product) can be transferred at high efficiencies into the eukaryotic cells by using lipofection methods.

Compared to the plasmid based genome editing procedures we observed less toxicity, increased specificity and remove the introduction of foreign DNA (plasmid backbone) into the eukaryotic cells. This makes the genome editing procedure much cleaner and therefore our group encourage colleagues in the field to start using synthetic guide RNAs.

LMU
BD
Radboud University
PAMM
Vitens